Jefferies analyst Faisal Kurshid assumed coverage of Kymera Therapeutics (KYMR) with a Buy rating and a price target of $110, down from $122. STAT6 degrader KT-621 holds the promise of being “oral Dupixent,” and it has delivered everything needed so far across preclinical, Phase 1 healthy volunteer and early patient data, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $128 from $90 at UBS
- Kymera Therapeutics price target raised to $100 from $95 at Stephens
- Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward
- Kymera Therapeutics price target raised to $120 from $110 at Citi
- Kymera Therapeutics Signals Strong Momentum In Earnings Call